# SECOND REGULAR SESSION HOUSE COMMITTEE SUBSTITUTE FOR HOUSE BILL NO. 1554

# 99TH GENERAL ASSEMBLY

5285H.04C

D. ADAM CRUMBLISS, Chief Clerk

# AN ACT

To repeal sections 191.480, 192.945, 192.947, 195.207, 261.265, and 263.250, RSMo, and to enact in lieu thereof six new sections relating to the use of investigational drugs, with penalty provisions.

Be it enacted by the General Assembly of the state of Missouri, as follows:

	Section A. Sections 191.480, 192.945, 192.947, 195.207, 261.265, and 263.250, RSMo,
2	are repealed and six new sections enacted in lieu thereof, to be known as sections 191.480,
3	192.945, 192.947, 195.207, 261.265, and 263.250, to read as follows:
	191.480. 1. For purposes of this section, the following terms shall mean:
2	(1) "Dispensing organization", an entity licensed under chapter 261 to distribute
3	medical cannabis;
4	(2) "Eligible patient", a person who meets all of the following:
5	(a) Has a terminal illness;
6	(b) Has considered all other treatment options currently approved by the [United States]
7	federal Food and Drug Administration and all relevant clinical trials conducted in this state;
8	(c) Has received a prescription or recommendation from the person's physician for an
9	investigational drug, biological product, or device;
10	(d) Has given written informed consent which shall be at least as comprehensive as the
11	consent used in clinical trials for the use of the investigational drug, biological product, or device
12	or, if the patient is a minor or lacks the mental capacity to provide informed consent, a parent or
13	legal guardian has given written informed consent on the patient's behalf; and
14	(e) Has documentation from the person's physician that the person has met the
15	requirements of this subdivision;

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

[(2)] (3) "Investigational drug, biological product, or device", a drug, biological product,
 or device, any of which are used to treat the patient's terminal illness, that has successfully
 completed phase one of a clinical trial but has not been approved for general use by the [United
 States] federal Food and Drug Administration and remains under investigation in a clinical trial.
 The term shall not include Schedule I controlled substances except for medical cannabis. The
 term shall include medical cannabis from a dispensing organization;

[(3)] (4) "Terminal illness", a disease that without life-sustaining procedures will result
 in death in the near future or a state of permanent unconsciousness from which recovery is
 unlikely.

25 2. A **dispensing organization or** manufacturer of an investigational drug, biological 26 product, or device may make available the **dispensing organization's or** manufacturer's 27 investigational drug, biological product, or device to eligible patients under this section. This 28 section does not require that a **dispensing organization or** manufacturer make available an 29 investigational drug, biological product, or device to an eligible patient. A **dispensing** 30 **organization or** manufacturer may:

(1) Provide an investigational drug, biological product, or device to an eligible patientwithout receiving compensation; or

33 (2) Require an eligible patient to pay the costs of or associated with the manufacture of34 the investigational drug, biological product, or device.

35 3. This section does not require a health care insurer to provide coverage for the cost of 36 any investigational drug, biological product, or device. A health care insurer may provide 37 coverage for an investigational drug, biological product, or device.

4. This section does not require the department of corrections to provide coverage forthe cost of any investigational drug, biological product, or device.

5. Notwithstanding any other provision of law to the contrary, no state agency or regulatory board shall revoke, fail to renew, or take any other action against a physician's license issued under chapter 334 based solely on the physician's recommendation to an eligible patient regarding prescription for or treatment with an investigational drug, biological product, or device. Action against a health care provider's Medicare certification based solely on the health care provider's recommendation that a patient have access to an investigational drug, biological product, or device is prohibited.

6. [If a provision of this section or its application to any person or circumstance is held invalid, the invalidity does not affect other provisions or applications of this section that can be given effect without the invalid provision or application, and to this end the provisions of this section are severable] Notwithstanding any other provision of law to the contrary, no state agency or regulatory board shall revoke, fail to renew, or take any other action against a

dispensing organization's license issued under chapter 261 based solely on the dispensing
organization's sale of medical cannabis to an eligible patient under this section.

54 7. If the clinical trial is closed due to lack of efficacy or toxicity, the drug shall not be 55 offered. If notice is given on a drug, product, or device taken by a patient outside of a clinical 56 trial, the pharmaceutical company or patient's physician shall notify the patient of the information 57 from the safety committee of the clinical trial.

8. Except in the case of gross negligence or willful misconduct, any person who manufactures, imports, distributes, prescribes, dispenses, or administers an investigational drug or device to an eligible patient with a terminal illness in accordance with this section shall not be liable in any action under state law for any loss, damage, or injury arising out of, relating to, or resulting from:

(1) The design, development, clinical testing and investigation, manufacturing, labeling,
 distribution, sale, purchase, donation, dispensing, prescription, administration, or use of the drug
 or device; or

66

(2) The safety or effectiveness of the drug or device.

9. Any official, employee, or agent of this state who blocks or attempts to block
access of an eligible patient to an investigational drug, biological product, or device is
guilty of a class A misdemeanor.

10. If any provision of this section or its application to any person or circumstance is held invalid, such determination shall not affect the provisions or applications of this section which may be given effect without the invalid provision or application, and to that end the provisions of this section are severable.

192.945. 1. As used in this section, the following terms shall mean:

- (1) "Department", the department of health and senior services;
- 3 (2) "Hemp extract", as such term is defined in section 195.207;
- 4

2

- (3) "Hemp extract registration card", a card issued by the department under this section;
- 5 (4) "Intractable epilepsy", epilepsy that as determined by a neurologist does not respond 6 to three or more treatment options overseen by the neurologist;
- 7
- (5) "Medical cannabis", as such term is defined in section 195.207;
- 8 (6) "Medical cannabis registration card", a card issued by the department under 9 this section;

[(5)] (7) "Neurologist", a physician who is licensed under chapter 334 and board certified
 in neurology;

12 [(6)] (8) "Parent", a parent or legal guardian of a minor who is responsible for the minor's
 13 medical care;

4

[<del>(7)</del>] (9) "Registrant", an individual to whom the department issues a hemp extract or
medical cannabis registration card under this section;
(10) "Terminal illness", a disease or condition as defined in section 191.480.
2. The department shall issue a hemp extract or medical cannabis registration card to

18 an individual who:

19 (1) Is eighteen years of age or older;

(2) Is a Missouri resident;

21 (3) Provides the department with a statement signed by a neurologist **or physician** that:

(a) Indicates that the individual suffers from intractable epilepsy and may benefit from
 treatment with hemp extract or that the individual suffers from a terminal illness and may
 benefit from treatment with medical cannabis at the same dosage and with the same
 method of smokeless administration used in a clinical trial; [and]

(b) Indicates that the individual has considered all other treatment options
 currently approved by the federal Food and Drug Administration and all relevant clinical
 trials conducted in this state; and

(c) Is consistent with a record from the neurologist or physician concerning the
individual contained in the database described in subsection [9] 11 of this section;

31 (4) Pays the department a fee in an amount established by the department under
32 subsection [6] 8 of this section; and

33 (5) Submits an application to the department on a form created by the department that34 contains:

35

20

(a) The individual's name and address;

36 (b) A copy of the individual's valid photo identification; and

37 (c) Any other information the department considers necessary to implement the38 provisions of this section.

39 3. The department shall issue a hemp extract or medical cannabis registration card to40 a parent who:

41 (1) Is eighteen years of age or older;

42 (2) Is a Missouri resident;

43 (3) Provides the department with a statement signed by a neurologist **or physician** that:

44 (a) Indicates that a minor in the parent's care suffers from intractable epilepsy and may

45 benefit from treatment with hemp extract or suffers from a terminal illness and may benefit
46 from medical cannabis at the same dosage and with the same method of smokeless

47 administration used in a clinical trial; [and]

trials conducted in this state; and

48

49

50

currently approved by the federal Food and Drug Administration and all relevant clinical

(b) Indicates that the individual has considered all other treatment options

51 (c) Is consistent with a record from the neurologist or physician concerning the minor 52 contained in the database described in subsection [9] 11 of this section; 53 (4) Pays the department a fee in an amount established by the department under 54 subsection [6] 8 of this section; and 55 (5) Submits an application to the department on a form created by the department that 56 contains: 57 (a) The parent's name and address; 58 (b) The minor's name; 59 (c) A copy of the parent's valid photo identification; and 60 (d) Any other information the department considers necessary to implement the provisions of this section. 61 62 4. The department shall maintain a record of the name of each registrant and the name of each minor receiving care from a registrant. 63 64 5. The department shall promulgate rules to: 65 (1) Implement the provisions of this section including establishing the information the applicant is required to provide to the department and establishing in accordance with 66

67 recommendations from the department of public safety the form and content of the hemp extract
68 and medical cannabis registration [eard] cards; and

(2) Regulate the distribution of hemp extract from a cannabidiol oil care center and
medical cannabis from a cannabis care center, as defined in section 261.265, to a registrant,
which shall be in addition to any other state or federal regulations[; and].

6. The department shall publish a list of diseases and conditions for which a medical cannabis registration card may be issued. The list shall only contain terminal illnesses as defined under section 191.480. The department shall publish a list of diseases and conditions for which a hemp extract registration card may be issued. The list shall only contain intractable epilepsy.

77 7. The department may promulgate rules to authorize clinical trials involving hemp78 extract and medical cannabis.

79 [6.] 8. The department shall establish fees that are no greater than the amount necessary
80 to cover the cost the department incurs to implement the provisions of this section.

81 [7:] 9. The registration cards issued under this section shall be valid for one year and 82 renewable if at the time of renewal the registrant meets the requirements of either subsection 2 83 or 3 of this section.

84 [8.] 10. The neurologist or physician who signs the statement described in subsection 85 2 or 3 of this section shall:

(1) Keep a record of the neurologist's or physician's evaluation and observation of a
 patient who is a registrant or minor under a registrant's care including the patient's response to
 hemp extract or medical cannabis; and

89

(2) Transmit the record described in subdivision (1) of this subsection to the department.

90 [9.] 11. The department shall maintain a database of the records described in subsection
91 [8] 10 of this section and treat the records as identifiable health data.

92 [10.] 12. The department may share the records described in subsection [9] 11 of this
93 section with a higher education institution for the purpose of studying hemp extract or medical
94 cannabis.

95 [11.] 13. Any rule or portion of a rule, as that term is defined in section 536.010, that is 96 created under the authority delegated in this section shall become effective only if it complies 97 with and is subject to all of the provisions of chapter 536 and, if applicable, section 536.028. 98 This section and chapter 536 are nonseverable and if any of the powers vested with the general 99 assembly pursuant to chapter 536 to review, to delay the effective date, or to disapprove and 100 annul a rule are subsequently held unconstitutional, then the grant of rulemaking authority and 101 any rule proposed or adopted after July 14, 2014, shall be invalid and void.

192.947. 1. No individual or health care entity organized under the laws of this state 2 shall be subject to any adverse action by the state or any agency, board, or subdivision thereof, including civil or criminal prosecution, denial of any right or privilege, the imposition of a civil 3 4 or administrative penalty or sanction, or disciplinary action by any accreditation or licensing board or commission if such individual or health care entity, in its normal course of business and 5 6 within its applicable licenses and regulations, acts in good faith upon or in furtherance of any order or recommendation by a neurologist or physician authorized under section 192.945 7 8 relating to the medical use and administration of hemp extract or medical cannabis with respect 9 to an eligible patient.

The provisions of subsection 1 of this section shall apply to the recommendation,
 possession, handling, storage, transfer, destruction, dispensing, or administration of hemp extract
 and medical cannabis, including any act in preparation of such dispensing or administration.

3. This section shall not be construed to limit the rights provided under law for a patient
to bring a civil action for damages against a physician, hospital, registered or licensed practical
nurse, pharmacist, any other individual or entity providing health care services, or an employee
of any entity listed in this subsection.

195.207. 1. As used in sections 192.945, 261.265, 261.267, and this section, the term 2 ["hemp extract"] "medical cannabis" shall mean [an] a noncombustible extract from a

3 cannabis plant or a **noncombustible** mixture or preparation containing cannabis plant material.

- 4 "Hemp extract" shall mean the same, except that it:
- 5

6

(1) Is composed of no more than three-tenths percent tetrahydrocannabinol by weight;(2) Is composed of at least five percent cannabidiol by weight; and

7 (3) Contains no other psychoactive substance.

8 2. Notwithstanding any other provision of this chapter, an individual who has been 9 issued a valid hemp extract **or medical cannabis** registration card under section 192.945, or is 10 a minor under a registrant's care, and possesses or uses hemp extract **or medical cannabis** is not 11 subject to the penalties described in this chapter for possession or use of the hemp extract **or** 12 **medical cannabis** if the individual:

(1) Possesses or uses the hemp extract only to treat intractable epilepsy or medical
cannabis only to treat a terminal illness, as such terms are defined in section 192.945;

15 (2) Originally obtained the hemp extract or medical cannabis from a sealed container 16 with a label indicating the hemp extract's or medical cannabis' place of origin and a number that 17 corresponds with a certificate of analysis and a warning label with all possible side effects;

(3) Possesses, in close proximity to the hemp extract or medical cannabis, a certificateof analysis that:

20 (a) Has a number that corresponds with the number on the label described in subdivision21 (2) of this subsection;

(b) Indicates the hemp extract's or medical cannabis' ingredients including its
 percentages of tetrahydrocannabinol and cannabidiol by weight;

(c) Is created by a laboratory that is not affiliated with the producer of the hemp extract
 or medical cannabis and is licensed in the state where the hemp extract or medical cannabis
 was produced; and

- 27
- (d) Is transmitted by the laboratory to the department of health and senior services; and

(4) Has a current hemp extract or medical cannabis registration card issued by the
 department of health and senior services under section 192.945.

30 3. Notwithstanding any other provision of this chapter, an individual who possesses
 31 hemp extract or medical cannabis lawfully under subsection 2 of this section and administers
 32 hemp extract or medical cannabis to a minor suffering from intractable epilepsy or a terminal
 33 illness is not subject to the penalties described in this chapter for administering the hemp extract

- 34 or medical cannabis to the minor if:
- 35
- (1) The individual is the minor's parent or legal guardian; and

36 (2) The individual is registered with the department of health and senior services as the37 minor's parent under section 192.945.

38 4. An individual who has been issued a valid hemp extract or medical cannabis 39 registration card under section 192.945, or is a minor under a registrant's care, may possess up to twenty ounces of hemp extract or medical cannabis pursuant to this section. Subject to any 40 rules or regulations promulgated by the department of health and senior services, an individual 41 42 may apply for a waiver if a physician provides a substantial medical basis in a signed, written statement asserting that, based on the patient's medical history, in the physician's professional 43 judgment, twenty ounces is an insufficient amount to properly alleviate the patient's medical 44 45 condition or symptoms associated with such medical condition.

261.265. 1. For purposes of this section, the following terms shall mean:

2 (1) "Cannabidiol oil care center", the premises specified in an application for a 3 cultivation and production facility license in which the licensee is authorized to distribute 4 processed hemp extract to persons possessing a hemp extract registration card issued under 5 section 192.945;

6 (2) "Cannabis care center", the premises specified in an application for a 7 cultivation and production facility license in which the licensee is authorized to distribute 8 processed medical cannabis to persons possessing a medical cannabis registration card 9 issued under section 192.945;

(3) "Cannabis cultivation and production facility", the land and premises in which
 the licensee is authorized to distribute processed medical cannabis to persons possessing
 a medical cannabis registration card issued under section 192.945;

(4) "Cannabis cultivation and production facility license", a license that authorizes
 the licensee to grow, cultivate, process, and possess medical cannabis;

(5) "Cannabis grower", an entity issued a cultivation and production facility license
 by the department of agriculture that produces medical cannabis for the treatment of
 terminal illnesses;

18

(6) "Department", the department of agriculture;

19 (7) "Hemp":

(a) All nonseed parts and varieties of the cannabis sativa plant, whether growing
 or not, that contain a crop-wide average tetrahydrocannabinol (THC) concentration that
 does not exceed the lesser of:

23 a

a. Three-tenths of one percent on a dry weight basis; or

b. The percent based on a dry weight basis determined by the federal Controlled
Substances Act under 21 U.S.C. Section 801, et seq.; and

- 26 **(b)** Any cannabis sativa seed that is:
- 27 **a. Part of a growing crop;**
- 28 **b.** Retained by a grower for future planting; or

9

## 29 c. For processing into or use as agricultural hemp seed.

30

38

## 31 This term shall not include industrial hemp commodities or products;

(8) "Hemp cultivation and production facility", the land and premises specified in an
 application for a cultivation and production facility license on which the licensee is authorized
 to grow, cultivate, process, and possess hemp and hemp extract;

[(3)] (9) "Hemp cultivation and production facility license", a license that authorizes the
 licensee to grow, cultivate, process, and possess hemp and hemp extract, and distribute hemp
 extract to its cannabidiol oil care centers;

[(4) "Department", the department of agriculture;

39 (5)] (10) "Hemp grower", a nonprofit entity issued a cultivation and production facility
 40 license by the department of agriculture that produces hemp extract for the treatment of
 41 intractable epilepsy;

42 [<del>(6) "Hemp":</del>

(a) All nonseed parts and varieties of the cannabis sativa plant, whether growing or not,
 that contain a crop-wide average tetrahydrocannabinol (THC) concentration that does not exceed

45 the lesser of:

46 <u>a. Three-tenths of one percent on a dry weight basis; or</u>

47 b. The percent based on a dry weight basis determined by the federal Controlled
 48 Substances Act under 21 U.S.C. Section 801, et seq.;

49 (b) Any cannabis sativa seed that is:

50 <u>a. Part of a growing crop;</u>

51 b. Retained by a grower for future planting; or

- 52 <u>c. For processing into or use as agricultural hemp seed.</u>
- 53

54 This term shall not include industrial hemp commodities or products;]

[(7)] (11) "Hemp monitoring system", an electronic tracking system that includes, but is not limited to, testing and data collection established and maintained by the cultivation and production facility and is available to the department for the purposes of documenting the hemp extract production and retail sale of the hemp extract;

- 59 (12) "Medical cannabis":
- 60 (a) All nonseed parts and varieties of the cannabis plant, whether growing or not;

61 **and** 

62 (b) Any cannabis seed that is:

63 **a. Part of a growing crop;** 

64 **b. Retained by a grower for future planting; or** 

65

c. For processing into or use as agricultural cannabis seed.

66 2. The department shall issue a cultivation and production facility license to an 67 entity to grow or cultivate the cannabis plant used to make medical cannabis, as defined in subsection 1 of section 195.207, on the entity's property if the entity has submitted to the 68 69 department an application as required by the department under subsection 9 of this section 70 and the entity meets all requirements of this section and the department's rules.

71 3. A cannabis grower may produce, manufacture, and distribute medical cannabis 72 as defined in section 195.207 for the treatment of persons suffering from a terminal illness 73 consistent with any and all state and local regulations regarding the production, 74 manufacture, or distribution of such product.

75 4. The department shall issue a hemp cultivation and production facility license to a 76 nonprofit entity to grow or cultivate the cannabis plant used to make hemp extract as defined in subsection 1 of section 195.207 or hemp on the entity's property if the entity has submitted to the 77 78 department an application as required by the department under subsection [7] 9 of this section[-] 79 and the entity meets all requirements of this section and the department's rules, and there are 80 fewer than two licensed cultivation and production facilities operating in the state].

81 [3.] 5. A hemp grower may produce and manufacture hemp and hemp extract, and 82 distribute hemp extract as defined in section 195.207 for the treatment of persons suffering from 83 intractable epilepsy as defined in section 192.945 consistent with any and all state or federal 84 regulations regarding the production, manufacture, or distribution of such product. [The 85 department shall not issue more than two cultivation and production facility licenses for the 86 operation of such facilities at any one time.]

87

[4.] 6. The department shall maintain a list of growers.

88 [5.] 7. All growers shall keep records in accordance with rules adopted by the 89 department. Upon at least three days' notice, the director of the department may audit the 90 required records during normal business hours. The director may conduct an audit for the 91 purpose of ensuring compliance with this section.

92

[6.] 8. In addition to an audit conducted in accordance with subsection [5] 7 of this 93 section, the director may inspect independently, or in cooperation with the state highway patrol 94 or a local law enforcement agency, any hemp or medical cannabis crop during the crop's growth 95 phase and take a representative composite sample for field analysis. If a hemp crop contains an 96 average tetrahydrocannabinol (THC) concentration exceeding the lesser of:

97

(1) Three-tenths of one percent on a dry weight basis; or

98 (2) The percent based on a dry weight basis determined by the federal Controlled 99 Substances Act under 21 U.S.C. Section 801, et seq.,

100

11

101 the director may detain, seize, or embargo the **hemp** crop.

102 [7.] 9. The department shall promulgate rules including, but not limited to:

(1) Application requirements for licensing, including requirements for the submissionof fingerprints and the completion of a criminal background check;

- 105 (2) Security requirements for cultivation and production facility premises, including, at 106 a minimum, lighting, physical security, video and alarm requirements;
- 107

(3) Rules relating to hemp **and cannabis** monitoring systems as defined in this section;

(4) Other procedures for internal control as deemed necessary by the department to
 properly administer and enforce the provisions of this section, including reporting requirements
 for changes, alterations, or modifications of the premises;

(5) Requirements that any hemp extract **or medical cannabis** received from a legal source be submitted to a testing facility designated by the department to ensure that such hemp extract **or medical cannabis** complies with the provisions of section 195.207 and to ensure that the hemp extract **or medical cannabis** does not contain any pesticides. Any hemp extract **or medical cannabis** that is not submitted for testing or which after testing is found not to comply with the provisions of section 195.207 shall not be distributed or used and shall be submitted to the department for destruction; and

(6) Rules regarding the manufacture, storage, and transportation of hemp, [and] hemp
extract, and medical cannabis, which shall be in addition to any other state or federal
regulations.

121 [8:] 10. Any rule or portion of a rule, as that term is defined in section 536.010, that is 122 created under the authority delegated in this section shall become effective only if it complies 123 with and is subject to all of the provisions of chapter 536 and, if applicable, section 536.028. 124 This section and chapter 536 are nonseverable, and if any of the powers vested with the general 125 assembly under chapter 536 to review, to delay the effective date, or to disapprove and annul a 126 rule are subsequently held unconstitutional, then the grant of rulemaking authority and any rule 127 proposed or adopted after July 14, 2014.

[9:] 11. All hemp and cannabis waste from the production of hemp extract or medical
cannabis shall either be destroyed, recycled by the licensee at the hemp or medical cannabis
cultivation and production facility, or donated to the department or an institution of higher
education for research purposes, and shall not be used for commercial purposes.

132 [10.] 12. In addition to any other liability or penalty provided by law, the director may 133 revoke or refuse to issue or renew a cultivation and production facility license and may impose 134 a civil penalty on a grower for any violation of this section, or section 192.945 or 195.207. The 135 director may not impose a civil penalty under this section that exceeds two thousand five 136 hundred dollars.

137 13. Notwithstanding any other provision of law to the contrary, a person who
138 commits any acts that are unlawful under section 191.480, 192.945, 192.947, 195.207,
139 261.265, or 263.250 with the intent to distribute medical cannabis to minors shall be guilty
140 of a class D felony.

141 14. Any manufacturing, storage, or testing of medical cannabis or any medical
142 cannabis product shall meet all requirements of the department of health and senior
143 services and all local health departments.

263.250. 1. The plant "marijuana", botanically known as cannabis sativa, is hereby
declared to be a noxious weed and all owners and occupiers of land shall destroy all such plants
growing upon their land. Any person who knowingly allows such plants to grow on his land or
refuses to destroy such plants after being notified to do so shall allow any sheriff or such other
persons as designated by the county commission to enter upon any land in this state and destroy
such plants.

2. Entry to such lands shall not be made, by any sheriff or other designated person to
destroy such plants, until fifteen days' notice by certified mail shall be given the owner or
occupant to destroy such plants or a search warrant shall be issued on probable cause shown. In

10 all such instances, the county commission shall bear the cost of destruction and notification.

**3.** The provisions of this section shall not apply to the licensed production of hemp

12 oil or medical cannabis under chapter 261.

1